Advertisement
Cancer Therapy: Clinical

Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab

Jesús G. Berdeja, Allan Hess, David M. Lucas, Paul O'Donnell, Richard F. Ambinder, Louis F. Diehl, Denise Carter-Brookins, Susan Newton and Ian W. Flinn
DOI: 10.1158/1078-0432.CCR-06-1860 Published 15 April 2007

Abstract

Purpose: Murine models have shown that antibody-dependent cellular cytotoxicity (ADCC) can be improved with addition of lymphokine-activated killer (LAK) cells to monoclonal antibodies. A pilot trial of rituximab and LAK cells in patients with rituximab-refractory CD20+ lymphoma was conducted to evaluate this approach.

Experimental Design: Ten patients received 3 million units/m2 of interleukin-2 (IL-2) i.v. qd on days 1 to 5 and leukapheresed on days 8, 9, and 10. The leukapheresis product was cultured with IL-2 for 48 h to produce LAK cells. Patients then received 375 mg/m2 i.v. rituximab and LAK cells on days 10, 11, and 12. The patients also received 3 million units/m2 of IL-2 i.v. for 5 days starting day 10. For safety purposes, the first three patients did not receive any LAK cell infusions.

Results: The LAK cell infusions improved the ADCC activity of peripheral blood lymphocytes compared with pretreatment activity and prevented the decline in ADCC seen after infusion of rituximab alone. Therapy was well tolerated and the most clinically significant toxicities were fever and fatigue. Two patients achieved a partial remission and five had stable disease.

Conclusions: The results from these studies suggest that the addition of LAK cells to rituximab augments ADCC in patients with rituximab-refractory lymphoma.

  • Rituximab
  • Antibody-dependent cellular cytotoxicity
  • Lymphoma

Rituximab is a chimeric anti-CD20 monoclonal antibody (mAb) with human γ-1 and κ constant regions and murine variable regions (1). In vitro, rituximab has significant antilymphoma activity. The underlying mechanisms that account for the antilymphoma activity of rituximab include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity, and direct induction of apoptosis (2, 3). Most of these in vitro studies were conducted using cell lines, and the potential contributions of these specific mechanisms in vivo are unclear. Studies in animal models using complement-deficient or complement-depleted hosts have suggested that the primary mechanism of in vivo tumor lysis induced by mAbs involves ADCC rather than complement-dependent cytotoxicity (4). Lending support to the notion that ADCC is an important mechanism of action of rituximab in vivo are clinical trials showing differential outcome dependent on distinct Fc receptor polymorphisms with differential affinities for the immunoglobulin Fc domain (5–7).

Engineering mAbs to be more effective in the induction of ADCC is an area of active research (8). However, potent ADCC requires competent host cellular effector mechanisms. ADCC, which is carried out by several distinct subsets of effector cells, including CTLs and natural killer (NK) cells, has been reported to be suboptimal in patients with cancer (9, 10). One approach to improve effector mechanisms and enhance ADCC activity is to activate NK cells and CTLs. For instance, the culture of peripheral blood lymphocytes (PBL) with interleukin-2 (IL-2) activates a subset of killer cells. This population of lymphokine-activated killer (LAK) cells is composed of mostly NK cells and CTLs with both acting as effector cells (11). Although initially promising, the infusion of LAK cells has largely been abandoned, as clinical trials failed to show efficacy, especially in lymphoma patients where few or no responses were seen (12–14).

Although the adoptive transfer of LAK cells in non–Hodgkin's lymphoma patients has had minimal effect in vivo when used by itself, it is unknown whether its effects are different in the setting of bound antibody. Numerous laboratory studies suggest that the addition of LAK cells improves the efficacy of tumor-specific mAbs. LAK cells are known to express human Fc receptors and can mediate ADCC (11, 15, 16). In a murine lymphoma model, the combination of in vitro–activated LAK cells and tumor-specific anti-Thy-1.1 IgG2a mAb had significantly greater antitumor activity than mAb therapy alone. Moreover, the combination of LAK cells and mAb was also superior to IL-2 and mAb therapy (17). Other investigators have shown similar results combining mAb therapy and LAK cells in various tumor cell lines and murine models for tumors ranging from lymphoma to colon cancer (18–25). Together, these results support the hypothesis that the addition of IL-2 and LAK cells to chimeric anti-CD20 antibodies may result in accentuated ADCC activity and possibly induce greater lymphoma cell death than that seen with anti-CD20 therapy alone.

To further explore the role of ADCC mechanisms in lymphoma patients given rituximab, the capacity of PBLs from patients to induce ADCC was examined before and after treatment with rituximab in correlative studies of a prior clinical trial population. The results from these studies suggest that ADCC activity in the lymphoma patients was inferior compared with normal controls. Moreover, ADCC activity decreased after the infusion of rituximab. These findings led us to conduct a pilot study to evaluate whether ADCC can be augmented by the adoptive transfer of LAK cells and subsequently enhance antilymphoma effects of rituximab in patients with non–Hodgkin's lymphoma.

Materials and Methods

Patient eligibility. PBL samples from eight patients with low-grade or mantle cell lymphoma were used in the preclinical study. These patients were concurrently enrolled in a clinical trial evaluating the addition of rituximab to autologous peripheral blood stem cell transplantation and thus had the good organ function and performance status required to receive high-dose therapy.

In the clinical trial, 10 patients with a diagnosis of CD20+ B-cell non–Hodgkin's lymphoma were enrolled. All patients had been previously treated with rituximab and were considered refractory to this therapy (achieved less than a partial remission or progressed within 6 months of rituximab therapy). All patients enrolled met eligibility criteria, including preserved organ function defined as a left ventricular ejection fraction ≥45%; serum creatinine ≤2.0 mg/dL; total bilirubin ≤2.0 mg/dL; forced expiratory volume 1, forced vital capacity, and diffusing capacity of the lung for carbon monoxide ≥75% of predicted values; absolute neutrophil count ≥1 × 109/L; and platelets ≥75 × 109/L. Patients were excluded for any of the following: HIV infection, central nervous system involvement by lymphoma at the time of enrollment, receipt of organ allografts or allogeneic stem cell transplant, and previous exposure to i.v. IL-2. The use of steroids or other immunosuppressive medications as a premedication to rituximab or at any other time was not allowed.

All participating patients signed informed consent before enrolling in these studies in accordance with current Food and Drug Administration, National Cancer Institute, state, federal, and institutional regulations.

Study design. In the initial preclinical study, ADCC was measured from heparinized blood drawn from patients receiving rituximab for in vivo purging purposes during stem cell mobilization for use in peripheral blood stem cell as described previously (26). These patients received 375 mg/m2 rituximab 3 days before receiving cyclophosphamide, which was used to mobilize the hematopoietic stem cells. ADCC samples were drawn from these patients at baseline 1 h after completion of rituximab infusion and on day 3 before receiving cyclophosphamide. Peripheral blood from 10 normal volunteers served as controls.

The clinical trial was a two-part study of patients with relapsed CD20+ B-cell lymphoma. Part one of the trial consisted of three patients treated with i.v. IL-2 and rituximab but received no LAK cell infusions. The purpose of this first part was to assess feasibility and safety of the combination of IL-2 and rituximab given in this format. The remaining patients proceeded to part two and were treated with i.v. IL-2, rituximab, and LAK cell infusions (Fig. 1 ). All patients received 3 million units/m2 IL-2 by 24-h continuous i.v. infusion on days 1 to 5 and again on days 10 to 14. Approximately 36 h following the completion of the first 5 days of IL-2 infusion (days 8, 9, and 10), patients underwent 3 consecutive days of leukapheresis for PBL collection. Patients required either a large bore peripheral or central venous catheter. Leukapheresis was done using a Cobe Spectra (Lakewood, CO) apheresis machine. The goal for each leukapheresis collection was 5.0 × 1010 mononuclear cells, but any amount collected was processed. The number of circulating absolute lymphocytes was checked and recorded before each daily leukapheresis session to assess degree of lymphocytosis from the IL-2 treatment. Likewise, the numbers of mononuclear cells collected per daily leukapheresis session were recorded. Serial monitoring of serum calcium was done and supplemental calcium was given as needed.

Fig. 1.
Fig. 1.

Treatment schema. IL-2 (3 million units/m2) was infused by 24 h continuous i.v. infusion on days 1 to 5 and again on days 10 to 14. On days 8, 9, and 10, patients underwent leukapheresis for the production of LAK cells. Following the final leukapheresis, 375 mg/m2 i.v. rituximab was given followed 1 h later by infusion of LAK cells i.v. over 30 min on days 10, 11, and 12. Note that the first three patients did not receive any infusions of LAK cells.

Following the final leukapheresis, 375 mg/m2 i.v. rituximab was given followed 1 h later by infusion of LAK cells i.v. over 30 min on days 10, 11, and 12. Note that the three patients in part one did not undergo leukapheresis or receive any infusions of LAK cells.

Summary of LAK cell generation. This procedure was done with good laboratory practice with appropriate documentation in a clinical graft engineering laboratory that is Joint Commission on Accreditation of Healthcare Organizations and American Association of Blood Banks accredited.

The PBLs collected from each session were cultured in vitro in the setting of high-dose IL-2 for the generation of LAK cells as described previously (27). Briefly, cells were cultured in serum-free medium (X-VIVO10, BioWhittaker, Walkersville, MD) with glutamine, streptomycin, gentamicin, and 1,000 units/mL IL-2 at a concentration of 2.5 × 106 to 5.0 × 106 cells/mL. Cells were cultured in 1,000 mL aliquots in 3 L Lifecell bags (Nexell, Inc., Irvine, CA) at 37°C for 2 days in a Stericult Tissue Culture Incubator (ThermoQuest Corp., Austin, TX). After incubation, cells were washed, concentrated, and suspended in a 5% human serum albumin solution on COBE2991 and 75,000 units of IL-2 mixture for infusion. During incubation, bags were mixed and inspected for clumping and medium color change (pH change). Microbial, fungal and Mycoplasma cultures, and endotoxin testing was done before infusion.

Cytotoxic in vitro efficacy and ADCC determination of LAK cells and PBLs. Cytotoxic in vitro efficacy of LAK cells was tested using the 51Cr release assay against NK-resistant Raji tumor cell lines and NK-sensitive human erythroleukemia K562 cell lines. Effector cells were obtained directly from the LAK product (2 × 107 cells) or extracted from a heparinized whole blood sample (20 cm3). Effector cells were isolated using Ficoll-Hypaque, washed twice with RPMI 1640, and resuspended in culture medium (RPMI 1640 + 10% FCS). Cell concentration was adjusted to 3 × 106/mL. Tumor cell lines were incubated with 250 μCi 51Cr for 1 h at 37°C H2O bath, washed thrice with 5% culture medium, and resuspended with culture medium. Cell count was adjusted to 3 × 104 targets/mL. E:T ratios were as follows: 100:1, 50:1, 25:1, 12.5:1, 6.25:1, 3.13:1, 1.57:1, and 0.78:1. All determinations were done in six replicates. Plates were incubated for 4 h at 37°C, 5% CO2 humidified atmosphere. Plates were centrifuged for 5 min at 1,000 rpm, and 100 μL of supernatant were harvested and placed in glass culture tubes (Kimble, Vineland, NJ) measuring 6 × 50 mm. The samples were counted in a gamma counter (Packard Instrument, Waltham, MA), and percentage specific lysis was calculated as follows: minimum release − 100 μL targets + 100 μL culture medium → harvest 100 μL supernatant; maximum release was obtained by adding 1 mol/L HCl to each well, refluxing, and then harvesting 100 μL from each well. The ADCC assay was done in a similar manner to above. However, the CD20+ SB cell line was used as the target. Target cells were incubated on ice for 30 min after 51Cr incubation with or without 50 μg rituximab or PBS-A1x control.

Foxp3 gene expression to evaluate regulatory T cells. Foxp3, CD4, and CD8 gene expression in peripheral blood mononuclear cells was assessed by quantitative PCR as described previously (28, 29). Briefly, RNA was extracted from peripheral blood mononuclear cells and converted to cDNA. The levels of Foxp3, CD4, and CD8 transcripts were determined by quantitative PCR multiplexing against the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase. Data are presented as the ratio of the target gene levels against the levels of glyceraldehyde-3-phosphate dehydrogenase.

Analysis of FcγRIIa-131H/R and FcγRIIIa-158V/F polymorphism. PBL samples from three randomly selected patients receiving LAK cells were analyzed for the FcγRIIa-131H/R and FcγRIIIa-158V/F polymorphisms. DNA was extracted using the QIAamp kit according to the manufacturer's instructions (Qiagen, Valencia, CA). Assessment of the FcγRIIa-131H/R and FcγRIIIa-158V/F polymorphisms was done essentially as described previously (6). All samples were analyzed in duplicate.

Analysis. All enrolled patients who received at least one dose of IL-2 were included in the safety analysis. The number of adverse events was calculated and assigned to each component of the treatment as best as possible. If an adverse event occurred more than once for a given patient, the most severe grade was used to characterize the event.

Clinical responses were assessed using standard criteria for complete response, partial response, stable disease, and progressive disease. Duration of response was determined as the time between the best-documented response and first documentation of progressive disease, death, or loss to follow-up.

Results of experimental points obtained from multiple experiments were reported as the mean ± 1 SD of the mean. Differences between two means were determined using a t test for independent values and reported with their corresponding P values.

Results

As part of the initial preclinical study, ADCC of PBLs was measured in 8 patients and 10 controls (Fig. 2 ). Similar results were seen at various E:T ratios, and data from the 40:1 ratio are shown. Mean specific lysis was 37.9% (range, 23.9-51.8%) in patients and 59.7% (range, 52.4-67%) in controls (P = 0.0035). The patient baseline ADCC dropped to 5.5% (range, 0-11.1%) 1 h after rituximab was infused (P = 0.0002). ADCC improved at 24 h (mean, 28.1%; range, 10.6-45.6%; P = 0.32; Fig. 2).

Fig. 2.
Fig. 2.

ADCC activity at an E:T ratio of 40:1. ADCC data from the preclinical pilot study depicting the median % specific lysis measured using PBLs as effector cells and the CD20+ SB cell line used as target in the setting of rituximab at various time points. Baseline, PBLs collected before systemic rituximab exposure; 1 and 24 h after rituximab, time points following systemic rituximab exposure.

In the clinical study, 10 patients (median age, 63; range, 46-66) with a median of 6 (range, 3-10) prior therapies were enrolled. Histology was seven follicular center cell, two small lymphocytic, and one diffuse large cell. All patients were refractory to rituximab.

The median mononuclear cell collection for each of three consecutive leukapheresis products was 5.49 ± 2.0 × 1010, 6.22 ± 2.1 × 1010, and 2.73 ± 1.2 × 1010, respectively. These cells were subsequently used for the creation of LAK cells. The median numbers of LAK cells per infusion were 1.96 ± 1.5 × 1010, 1.68 ± 1.4 × 1010, and 0.56 ± 0.6 × 1010, respectively. The median total of 3.52 ± 2.4 × 1010 (range, 1.70 × 1010 to 8.72 × 1010) LAK cells was infused per patient.

Three patients were entered onto part one of the study and tolerated therapy relatively well. The most clinically significant toxicities were fever and fatigue. Transient grade 2 and 3 anemia and thrombocytopenia were noted in patients with baseline cytopenias, resolving once IL-2 infusion was discontinued. Seven patients were entered onto part two of the study, which included leukapheresis and LAK cell infusions. One patient was withdrawn from study therapy before receiving LAK cells due to elevation of liver transaminases from the IL-2. The remaining patients all had similar toxicities as observed in part 1 of this trial, mostly attributed to the IL-2 infusions with the exception of higher-grade hematotoxicity requiring transfusions of platelets and RBCs mostly as a consequence of the serial leukapheresis. LAK cell infusions were very well tolerated, except for one patient who had a grade 3 allergic-type reaction during each infusion. Toxicity was transient and resolved shortly after infusion. Toxicities in all patients attributable to each component of their treatment are outlined in Table 1 . One patient received steroids at another institution and was not evaluable for response. Of the remaining eight evaluable patients, two patients achieved a partial remission and four patients had stable disease. The median duration of response was 163 days (range, 137-498 days; see Table 2 ).

View this table:
Table 1.

Toxicities according to National Cancer Institute Common Toxicity Criteria

View this table:
Table 2.

Patient characteristics and results of all patients enrolled

Flow cytometry measuring CD45, CD20, CD3, CD4, CD8, and CD56 was used to assess the composition of lymphocytes in samples from peripheral blood and LAK products. The treatment as given achieved the expected expansion of T lymphocytes and NK cells while suppressing B lymphocytes. The NK cell compartment at all time points was increased when compared with baseline values before any study therapy (median NK cells/mm3 at baseline or at days 0, 8, 9, 10, and 30 were 81, 301, 162, 130, and 328, respectively; P = 0.19). Interestingly, the absolute numbers of NK cells seemed to decrease as a result of leukapheresis in preparation for LAK cells, but rebounded following completion of study treatment, as evidenced by the 1-month evaluation point (Fig. 3 ). These data indicate that the use of moderate dose IL-2 and adoptive transfer of LAK cells as given in this study resulted in the acute and prolonged expansion of the NK cell population.

Fig. 3.
Fig. 3.

Median peripheral blood NK cells/mm3. The values correspond to the median absolute number of CD56+ cells in the PBLs sampled at the following time points: day 0 (baseline, before any study therapy), day 8 (after first 5 d IL-2 but before first leukapheresis), day 9 (after first leukapheresis), day 10 (after second leukapheresis), and day 30 (2-3 wks after completion of study therapy).

LAK cells were activated appropriately by our approach and were able to carry out specific lysis of both NK-sensitive erythroleukemia K562 and NK-resistant Raji tumor cell lines. In addition, LAK cells were more cytotoxic than the PBLs collected from the same patient before incubation with IL-2. At an E:T ratio of 12.5, specific lysis of the SB20 cell increased from 4.3% with PBLs to 36.5% (P = 0.01) with LAK cells. Furthermore, LAK cells were more potent in carrying out ADCC with rituximab against the CD20+ SB cell line than PBLs (42% LAK cells versus 11% PBLs; P = 0.03).

The ability of PBLs to carry out ADCC at various times during the study treatment was determined by measuring the percentage specific lysis of a CD20+ SB cell line in the setting of rituximab at an E:T ratio of 12.5. The percentage specific lysis at baseline, following 5 days of IL-2 but before any LAK cell infusions, following LAK cell infusions, and day 30 was 8.75, 11.4, 23.2, and 13.1, respectively (Fig. 4 ). The highest ADCC activity corresponded to PBLs collected soon after infusion of LAK cells, with the change from baseline reaching near statistical significance (P = 0.08). The measured ADCC activity after IL-2 only and at day 30 was higher than baseline, but the difference was not statistically significant (P = 0.23 and 0.44, respectively).

Fig. 4.
Fig. 4.

ADCC activity at an E:T ratio of 12.5. Mean specific lysis measured at an E:T ratio of 12.5, where PBLs from all evaluable patients were used as effector cells and the CD20+ SB cell line used as target in the setting of rituximab. Baseline samples, PBLs taken from patients before any study therapy; Pre LAK samples, PBLs taken from patients after IL-2 therapy but before LAK cell infusions; Post LAK samples, PBLs taken from patients after IL-2 therapy and LAK cell infusions; Day 30 samples, PBLs taken from patients 2 to 3 wks after completion of all study therapy.

Furthermore, the ADCC activity of PBLs in relation to first rituximab exposure is depicted in Fig. 5 . The percentage specific lysis for the two time points before rituximab exposure (baseline and after 5 days of IL-2) is 8.75 and 11.4, respectively. The percentage specific lysis for the three time points following the first rituximab exposure (24 h, 48 h, and 3 weeks after first rituximab) is 11.2, 23.2, and 13.1, respectively. No decline in ADCC activity was seen following rituximab exposure. The trend toward increased ADCC activity following rituximab exposure did not reach statistical significance.

Fig. 5.
Fig. 5.

ADCC activity following rituximab in the clinical study. Median % specific lysis measured using PBLs as effector cells and the CD20+ SB cell line used as target at an E:T ratio of 12.5 in the setting of rituximab. Baseline, PBLs collected before systemic rituximab exposure; Pre Ritux/Post IL-2, PBLs collected after 5 d of i.v. IL-2 but before first rituximab infusion; 24 h post, 48 h post, and 3 wks post, time points following the first systemic rituximab exposure.

To test whether expansion of regulatory T cells played a role in the ADCC activity observed, the results of a representative experiment evaluating Foxp3 gene expression are illustrated in Fig. 6A . Evaluation of mRNA transcript levels revealed that at day 10 there was a slight increase (4-fold) compared with pretreatment levels. On day 12, the levels of Foxp3 mRNA transcript levels were markedly decreased (14-fold compared with pretreatment levels and >40-fold versus day 10 levels.) At day 30, Foxp3 mRNA transcript levels were dramatically decreased (>150-fold) compared with pretreatment levels. Interestingly, CD4 mRNA transcripts as an indicator of CD4 T cells did not significantly change over these time intervals (Fig. 6B). On the other hand, there was a significant drop in CD8 mRNA transcript levels, suggesting a reduction in the CD8 T-cell compartment (Fig. 6C). Virtually identical results were observed in two other patients.

Fig. 6.
Fig. 6.

Regulatory T-cell evaluation at baseline (pre), day 10, day 12, and day 30. A, results of Foxp3 gene expression. B, CD4 mRNA transcripts. C, CD8 mRNA transcripts. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

The results of the FcγRIIa-131H/R polymorphism revealed two patients to be homozygous for R/R and one patient was heterozygous for H/R. The results of the FcγRIIIa-158V/F polymorphism revealed two patients to be heterozygous for F/V and one patient was homozygous for V/V.

Discussion

ADCC seems to be an important mechanism of action of rituximab in patients with B-cell malignancies. Unfortunately, the results from the preclinical studies suggest that ADCC is suboptimal in patients with non–Hodgkin's lymphoma. Moreover, infusion of rituximab actually significantly decreases ADCC activity at least in the short term. In light of these findings, strategies aimed at optimizing ADCC in rituximab-treated patients become more important.

It is not clear why rituximab causes a transient decrease in ADCC activity in PBLs from patients with non–Hodgkin's lymphoma. One possible explanation is that rituximab causes saturation or depletion of the effector cells that mediate ADCC following infusion of the antibody. Interestingly, a shift of the immunophenotype of PBLs after rituximab was not observed. On the other hand, this decrease in ADCC activity following administration of rituximab was not observed in the setting of IL-2 and LAK cell infusions (Fig. 5). In fact, the expansion of NK cells with i.v. IL-2 and the infusion of LAK cells actually may have increased levels of ADCC activity following rituximab exposure.

Studies in animal models have shown that the combination of mAb, LAK cells, and IL-2 is far more effective compared with each agent used alone. The present studies confirm the efficacy of this approach in patients with lymphoma. NK cells can be effectively expanded in vivo by the administration of i.v. IL-2 given at moderate doses. IL-2 at moderate doses is well tolerated and induces a rapid and durable expansion of the NK cell component of PBLs as has been reported by others with similar or alternate IL-2 dosing schedules (27, 30–32). The NK expansion occurred quickly after only 5 days of i.v. IL-2 exposure and was most pronounced at 1 month persisting 2 to 3 weeks following cessation of IL-2 treatment as depicted in Fig. 3. The absolute NK numbers were transiently decreased around the day 9 and 10 evaluations, presumably as a result of the leukapheresis procedures on days 8, 9, and 10. Notwithstanding, even after leukapheresis, the absolute numbers of NK cells were still higher than those seen at baseline before any IL-2 exposure.

Using specific lysis of a CD20+ SB cell line with and without rituximab, the ability of PBLs from this expanded population to act as effector cells and mediate ADCC was assessed. The results of the present studies show a minor increase in ADCC activity after exposure to IL-2. In addition, there was also a significant increase in ADCC activity after in vitro culturing of these effector cells with IL-2 to induce LAK cells, findings that were similar to previous studies in vitro (33). Interestingly, PBLs collected from patients after reinfusion of LAK cells were more potent mediators of ADCC than PBLs collected from patients after exposure to IL-2 but before the reinfusion of LAK cells. These data suggest that LAK cells not only can mediate ADCC but also may enhance total ADCC activity in vivo over and above the activity provided by exposure to IL-2 alone. This supports the hypothesis that augmentation of ADCC can be provided by adoptive transfer of LAK cells.

Other schedules or routes of administration of IL-2 may also improve the efficacy of rituximab. S.c. IL-2 increases the absolute number of NK cells, resulting in increased ADCC activity (34). This expansion is clearly dose related and appeared in patients receiving daily s.c. IL-2 and in patients receiving thrice weekly s.c. IL-2. Similarly, when we superimpose ADCC activity and absolute number of LAK cells, we see an increase in ADCC corresponding to expansion of NK cells as a result of increasing absolute numbers of NK cells after IL-2 exposure. This increased activity is still evident by the day 30 evaluation time point (Fig. 7 ). Interestingly, the highest levels of ADCC activity were not seen when the highest numbers of NK cells were detected in the peripheral blood. Rather, the highest levels of ADCC activity corresponded to the time shortly after adoptive transfer of LAK cells. These observations suggest that, although the quantity of effector cells is important, the functional capacity of these cells to mediate ADCC is more important. This has been previously raised in several other studies, indicating that, although low doses of IL-2 increase the number of NK cells, intermediate doses of this cytokine improve the function of these cells (35). Furthermore, expansion of regulatory T cells may also play an important role in suppression of ADCC (36). In the patients evaluated in the clinical study, there seemed to be a slight expansion measured following IL-2 infusion, but paradoxically, a sustained suppression was observed after infusion of LAK cells. Likewise, FcγRIIa and FcγRIIIa polymorphisms have been associated with improved mediation of ADCC and subsequent response to rituximab in patients with lymphoma (5–7) but not chronic lymphocytic leukemia (37). In three patients tested, only one contained the V/V homozygous polymorphism of FcγIIIa that would predict for a better clinical response to rituximab. This patient's clinical response was stable disease, and the ADCC activity was similar to the other two patients tested (data not shown). Unfortunately, PBLs were not available to do these studies on all patients. Although these results may be important in the interpretation of the clinical response, they do not explain the rise in ADCC activity seen after LAK cell infusion over baseline and IL-2 alone using each patient's PBLs as controls. In a larger cohort of patients, it would be interesting to see if increasing the number of effector cells, such as done here, with LAK cell infusions has a more robust effect in patients with FcγR polymorphisms predicting a stronger ADCC response.

Fig. 7.
Fig. 7.

Superimposed graphs of absolute NK cells and ADCC activity. Columns, median peripheral blood NK cells/mm3 of the evaluable patients at different time points. Line diamonds, mean specific lysis measured at an E:T ratio of 12.5, where PBLs from all evaluable patients were used as effector cells and the CD20+ SB cell line used as target in the setting of rituximab. The values for both NK cells and ADCC are a result of measurements of PBLs sampled at the following time points: day 0 (baseline, before any study therapy), day 8 (after IL-2 but before any leukapheresis or LAK cell infusions), days 10 to 12 (after completion of all leukapheresis and infusion of at least one LAK cell product), and day 30 (2-3 wks after completion of all study therapy).

Given the small numbers of patients in this pilot study, the therapeutic clinical utility of this treatment regimen should be interpreted with caution. Nonetheless, the stabilization and partial responses seen in this heavily pretreated and rituximab-refractory population are encouraging. The use of i.v. IL-2 as used in this pilot study to expand the NK cell population and to induce LAK cells requires that PBLs be collected with the in vitro induction of LAK activity followed by infusion in relatively short order. Perhaps, the use of alternate preparations, such as prolonged administration of s.c. IL-2, would allow for adequate expansion and collection of PBLs to induce LAK cells over a much longer period (34, 35, 38). These LAK cells could then be infused weekly or monthly to take full effect of the more standard dosing of rituximab and maximize exposure to LAK cells that mediate ADCC more effectively than “unprimed” PBLs. It is difficult to compare the results of this study to approaches using IL-2 alone (34, 35, 38). Patients enrolled in these studies are very different, although each study is fundamentally evaluating whether rituximab efficacy can be improved by augmenting ADCC activity in the patient. Importantly, each of these studies had encouraging enough results to continue the development of the regimen.

Rituximab was given on 3 consecutive days to each patient in this study to accommodate the logistical issues previously discussed and to maximize exposure to LAK cells. No unexpected toxicities were observed with more frequent doses of rituximab similar to data previously reported (39). Furthermore, the development of alternative methods of adoptive transfer of effector cells that is less cumbersome and/or dependent on patient scheduling may allow for a more flexible and more conventional dose scheduling.

In vitro and animal data suggest that augmentation of ADCC results in greater tumor lysis by mAbs. In this pilot study, we show that ADCC activity can be augmented by adoptively transferring in vitro–generated LAK cells and may overcome resistance to anti-CD20 mAb therapy in patients with non–Hodgkin's lymphoma who are rituximab refractory. Further studies will be needed to fully evaluate the efficacy of this approach.

Acknowledgments

We thank Emily Bright, Kathy Loper, and Donna Harris for their significant contributions in doing and securing much of the correlative study data.

Footnotes

  • Grant support: Genentech (I.W. Flinn).

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted February 2, 2007.
    • Received July 27, 2006.
    • Revision received December 5, 2006.

References

  1. ↵
    Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457–66.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Reff M, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435–45.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003;30:S3–8.
    OpenUrl
  4. ↵
    Badger CA, Anasetti C, Davis J, Bernstein ID. Treatment of malignancy with unmodified antibody. Pathol Immunopathol Res 1987;6:419–34.
    OpenUrlMedline
  5. ↵
    Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005;16:1675–82.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002;99:754–8.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940–7.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 2005;23:6421–8.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Jakobisiak M, Janowska-Wieczorek A, Dobaczewska H, et al. Decreased antibody-dependent cellular cytotoxicity in various types of leukaemia in man. Scand J Haematol 1981;27:181–5.
    OpenUrlMedline
  10. ↵
    Saijo N, Shimizu E, Irimajiri N, et al. Analysis of natural killer activity and antibody-dependent cellular cytotoxicity in healthy volunteers and in patients with primary lung cancer and metastatic pulmonary tumors. J Cancer Res Clin Oncol 1982;102:195–214.
    OpenUrlCrossRefMedline
  11. ↵
    Lindemann A, Hermann F, Oster W, Mertelsmann R. Lymphokine activated killer cells. Blut 1989;59:375–84.
    OpenUrlCrossRefMedline
  12. ↵
    Weber JS, Yang JC, Topalian SL, Schwartzentruber D, White CA, Rosenberg SA. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J Clin Oncol 1992;10:33–40.
    OpenUrlMedline
  13. Margolin KA, Aronson FR, Sznol M, et al. Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. J Immunother 1991;10:214–20.
    OpenUrlCrossRefMedline
  14. ↵
    Bernstein ZP, Vaickus L, Friedman N, et al. Interleukin-2 lymphokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease. J Immunother 1991;10:141–6.
    OpenUrlMedline
  15. ↵
    Shiloni E, Eisenthal A, Sachs D. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin-2. J Immunol 1987;138:1992–8.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Ortaldo JR, Mason A, Overton R. Lymphokine-activated killer cells: analysis of progenitors and effectors. J Exp Med 1986;164:1193–205.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Schultz KR, Klarnet JP, Peace DJ, et al. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells. Cancer Res 1990;50:5421–5.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Senba T, Kurori M, Arakawa F, et al. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model. Anticancer Res 1998;18:17–24.
    OpenUrlMedline
  19. Watanabe M, Kubota T, Kitajima M, Hakomorim S. Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice. Cancer Immunol Immunother 1993;37:245–50.
    OpenUrlCrossRefMedline
  20. Pendurthi TK, Parker R, Schlom J, Primus FJ. Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612. Int J Cancer 1990;46:1021–8.
    OpenUrlCrossRefMedline
  21. Pendurthi TK, Schlom J, Primus FJ. Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612. J Immunother 1991;10:2–12.
    OpenUrlCrossRefMedline
  22. Gill I, Agah R, Hu E, Mazumder A. Synergistic antitumor effects of interleukin-2 and the monoclonal Lym-1 against human Burkitt's lymphoma cells in vitro and in vivo. Cancer Res 1989;49:5377–9.
    OpenUrlAbstract/FREE Full Text
  23. Masucci G, Wersall P, Nielsen J, Nielsen HK, Wigzell H, Mellstedt H. Lymphokine activated killer cells in antibody dependent cellular cytotoxicity using MAb 17-1A: a combination of potential usefulness in tumor therapy. Hybridoma 1989;8:507–16.
    OpenUrlMedline
  24. Kawase I, Komuta K, Hara H, et al. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin-2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res 1988;48:1173–9.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Eisenthal A, Cameron RB, Uppenkamp I, Rosenberg SA. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. Cancer Res 1988;48:7140–5.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Flinn IW, O'Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000;6:628–32.
    OpenUrlCrossRefMedline
  27. ↵
    Clark JW, Smith JW, Steis RG, et al. Interleukin-2 and LAK cell therapy: analysis of a bolus IL-2 and a continuous infusion IL-2 regimen. Cancer Res 1990;50:7343–50.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Miura Y, Thoburn CJ, Bright EC, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004;104:2187–93.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Miura Y, Thoburn CJ, Bright EC, Chen W, Nakao S, Hess AD. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon γ may be critical mediators for the development of autologous GVHD. Blood 2002;100:2650–8.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Ettinghausen SE, Lipford EH III, Mule JJ, Rosenberg SA. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. J Immunol 1985;135:3623–35.
    OpenUrlAbstract
  31. Muul LM, Director EP, Hyatt CL, Rosenberg SA. Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. J Immunol Methods 1986;88:265–75.
    OpenUrlCrossRefMedline
  32. ↵
    Horton SA, Oldham RK, Yannelli JR. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2. Cancer Res 1990;50:1686–92.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Golay J, Manganini M, Facchinetti V, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003;88:1002–12.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004;10:2253–64.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Eisenbeis CF, Grainger A, Fischer B, et al. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res 2004;10:6101–10.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998;160:1212–8.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Farag S, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004;103:1472–4.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002;117:828–34.
    OpenUrlCrossRefMedline
  39. ↵
    Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153–64.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
View this article with LENS
Request Permissions
Open full page PDF
Article Alerts
Email Article
Citation Tools
Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab
Jesús G. Berdeja, Allan Hess, David M. Lucas, Paul O'Donnell, Richard F. Ambinder, Louis F. Diehl, Denise Carter-Brookins, Susan Newton and Ian W. Flinn
Clin Cancer Res April 15 2007 (13) (8) 2392-2399; DOI: 10.1158/1078-0432.CCR-06-1860
Permalink: Copy
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement

Related Articles

  • No related articles found.

Cited By...

More in this TOC Section